Alaunos Therapeutics, Inc. Severance Costs
Alaunos Therapeutics, Inc. (TCRT) reported Severance Costs of $1.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2025-03-31
- Alaunos Therapeutics, Inc. severance costs for the quarter ending 2023-12-31 was $900.00K.
- Alaunos Therapeutics, Inc. severance costs for the quarter ending 2023-09-30 was $400.00K.
- Alaunos Therapeutics, Inc. severance costs for the quarter ending 2021-12-31 was $120.00K.
- Alaunos Therapeutics, Inc. severance costs for the quarter ending 2021-06-30 was $800.00.
- Alaunos Therapeutics, Inc. severance costs for fiscal 2023 was $1.30M.
- Alaunos Therapeutics, Inc. severance costs for fiscal 2021 was $3.66M.
| Period end | Severance Costs 3 month | Severance Costs 3 month as first filed | Severance Costs 6 month | Severance Costs 9 month | Severance Costs 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.30M derived: sum of 2 quarters · filed 2025-03-31 | $1.30M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $400.00K 10-Q · filed 2023-11-14 | $400.00K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $3.66M 10-K · filed 2023-03-07 | |||
| 2021-09-30 | $3.54M 10-Q · filed 2021-11-08 | ||||
| 2021-06-30 | $800.00 10-Q · filed 2021-05-06 | $1.40K derived: sum of 2 quarters · filed 2021-05-06 | |||
| 2021-03-31 | $600.00 10-Q · filed 2021-05-06 | ||||
| 2013-06-30 | $1.70M 10-Q · filed 2014-10-30 | $1.60M 10-Q · filed 2013-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |